Callan Capital LLC Makes New $260,000 Investment in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Callan Capital LLC bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 9,180 shares of the medical equipment provider's stock, valued at approximately $260,000.

Several other large investors have also added to or reduced their stakes in SNN. River Road Asset Management LLC raised its holdings in shares of Smith & Nephew SNATS by 64.0% in the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock valued at $49,947,000 after acquiring an additional 792,829 shares in the last quarter. J. Goldman & Co LP purchased a new position in shares of Smith & Nephew SNATS during the 4th quarter valued at about $47,700,000. Brandes Investment Partners LP raised its holdings in shares of Smith & Nephew SNATS by 11.4% during the 4th quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock valued at $33,504,000 after buying an additional 138,994 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Smith & Nephew SNATS by 15.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 618,691 shares of the medical equipment provider's stock valued at $17,552,000 after buying an additional 83,341 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Smith & Nephew SNATS by 169.9% during the 4th quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after buying an additional 320,054 shares in the last quarter. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Stock Down 2.5%

Shares of NYSE SNN traded down $0.78 during mid-day trading on Friday, hitting $30.29. 1,285,641 shares of the stock traded hands, compared to its average volume of 821,369. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $31.72. The company has a market cap of $13.27 billion, a price-to-earnings ratio of 14.02, a PEG ratio of 0.96 and a beta of 0.69. The stock has a fifty day moving average price of $29.33 and a 200-day moving average price of $27.46.

Wall Street Analyst Weigh In

SNN has been the subject of a number of analyst reports. HSBC lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.